Quince Therapeutics, Inc. (QNCX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 167.82M |
| Enterprise Value | 180.37M |
| P/E Ratio | -0.14 |
| PEG Ratio | -0.02 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 0.3 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | 0.23 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -1.24 |
| Return On Equity | 18.23 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -142,000 |
| EBITDA | -80.62M |
| Net Income | -83.98M |
| Diluted EPS | -16.8 |
| Total Cash | 18.16M |
| Total Cash/Share | 3.63 |
| Total Debt | 406,000 |
| Total Debt/Equity | 0.03 |
| Current Ratio | 2.92 |
| Book Value Per Share | 3.13 |
| 52-Week Change | -92.42 |
| 52-Week High | 45.5 |
| 52-Week Low | 0.79 |
| Moving Average 50 Days | 1.2 |
| Moving Average 200 Days | 13.49 |
| Average Volume | 5.04M |
| Shares Outstanding | 5.57M |
| % Held by Institutions | N/A |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
| Last Split Date | April 13, 2026 |